Alnylam
the leading RNAi company; AMVUTTRA (vutrisiran) is approved for both forms of ATTR amyloidosis, with the first quarter of 2026 marking one year since the U.S. ATTR-CM launch — a significant commercial milestone;…
- Country
- United States
- Ticker
- ALNY
Commercial
siRNA (GalNAc)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Nucleic acid therapeutics (oligonucleotides) | therapeutics-platforms | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.